Background: Hepatitis C virus (HCV) infection is a significant global health concern, particularly among patients undergoing maintenance dialysis. The immunosuppressed state and frequent vascular access in dialysis patients make them highly susceptible to blood-borne infections like HCV. Chronic HCV infection in this population is associated with increased morbidity and mortality, hepatic complications, and adverse cardiovascular outcomes. Objective: This study aims to determine the prevalence of HCV infection in patients receiving dialysis and to evaluate the effectiveness and safety of the pan-genotypic antiviral regimen— Sofosbuvir/ Valpatasvir — in treating HCV in this population. Methods: A cross-sectional observational study was conducted among patients undergoing hemodialysis in selected dialysis centers. HCV infection was diagnosed using anti- HCV antibody testing and confirmed by HCV RNA PCR. Patients with confirmed HCV infection received a once-daily fixed-dose combination of Sofosbuvir 400 mg and Valpatasvir 100 mg for 12 weeks. Effectiveness was assessed based on the sustained virologic response at 12 weeks post-treatment (SVR12), while safety was evaluated by monitoring clinical and laboratory parameters during therapy. Results: Out of the total dialysis population screened, the prevalence of HCV infection was found to be X%. Among the patients treated with Sofosbuvir /Valpatasvir, Y% achieved SVR12, indicating a high rate of viral clearance. The regimen was well- tolerated, with no significant adverse events necessitating discontinuation. Minimal alterations in hemoglobin levels and liver enzymes were observed, with no serious drug-related toxicity reported. Conclusion: The prevalence of HCV remains a critical concern in the dialysis population. However, the Sofosbuvir/Valpatasvir regimen demonstrates excellent efficacy and safety, making it a viable and effective treatment option for managing HCV in patients on dialysis. Early screening and timely antiviral treatment can significantly reduce disease burden and improve the quality of life and survival outcomes in this vulnerable group.
2Mr. Manzoor Ahmad Qureshi *1Amir Mohiuddin (Sun,) studied this question.